Group 1: Stock Performance and Price Targets - AngioDynamics (ANGO) shares have increased by 5% over the past four weeks, closing at $6.69, with a mean price target of $13 indicating a potential upside of 94.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1, where the lowest estimate of $12 suggests a 79.4% increase, and the highest estimate of $14 indicates a 109.3% surge [2] Group 2: Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a positive trend in earnings estimate revisions [4][9] - The Zacks Consensus Estimate for the current year has increased by 0.8% due to one upward revision over the last 30 days, with no negative revisions [10] Group 3: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, serving as a starting point for further research [7]

Core Viewpoint - AngioDynamics, Inc. (ANGO) has faced a significant decline in stock performance, dropping 13.8% over the past three months, contrasting with the industry's slight gain of 0.3% and the S&P 500's growth of 6.9% [1][4][6] Financial Performance - In the first quarter of fiscal 2025, AngioDynamics reported overall net sales growth, but Med Device net sales experienced a decline due to inflationary pressures on raw materials, labor shortages, and freight costs, negatively impacting gross profit [3][8] - The company anticipates fiscal 2025 revenues between $282 million and $288 million, reflecting a growth of 4.2% to 6.4% from fiscal 2024, although the Zacks Consensus Estimate indicates a 6.5% decline compared to the previous fiscal year [7][18] Recent Developments - AngioDynamics announced the grant of Category I CPT for Irreversible Electroporation (IRE), which is expected to enhance reimbursement for healthcare providers and improve patient access to the NanoKnife System [2] - The company launched the Auryon 1.7mm catheter and is executing a full commercial launch of AlphaVac for pulmonary embolism in the U.S. and CE-marked countries [10] - AngioDynamics received European CE mark approval for the Auryon Atherectomy System, allowing it to market the system for treating Peripheral Artery Disease in Europe [14] Market Position and Strategy - The company is focusing on expanding cancer treatment options and improving patient quality of life, with strong market acceptance of its NanoKnife system for tumor treatment [8][9] - AngioDynamics is investing in three key technologies: AngioVac, Auryon, and NanoKnife, while also working to enhance the profitability of its other products [9] - The majority of growth in the first quarter was driven by the U.S. market, with expectations for continued growth from AlphaVac in the near term [12] Stock Valuation - AngioDynamics' forward 12-month price-to-sales (P/S) ratio is 0.9X, significantly lower than the industry average of 4.5X and its five-year median of 1.5X, indicating potential for growth [15][19]

Core Insights - AngioDynamics, Inc. (ANGO) announced that its Irreversible Electroporation (IRE) technology has received Current Procedural Terminology (CPT) Category I codes for treating lesions in the prostate and liver, indicating clinical efficacy and value in the medical community [1][2] - Following the announcement, ANGO's stock price increased by nearly 11.2% to $7.27, although the stock has declined 7.3% year-to-date compared to an 8.4% rise in the industry and a 22.7% increase in the S&P 500 [2] - The recognition of IRE under CPT Category I codes is expected to enhance billing precision for healthcare providers, leading to broader insurance coverage and defined reimbursement rates for NanoKnife procedures [3] Company Developments - The NanoKnife System, which utilizes IRE technology to ablate targeted cells without thermal energy, has shown solid growth and previously received FDA clearance for surgical ablation of soft tissue [4] - The system was also granted Breakthrough Device Designation by the FDA, highlighting its innovative approach in the medical field [4] - ANGO's market capitalization currently stands at $265.8 million, and the company reported an earnings surprise of 26.7% in the last quarter [2] Industry Prospects - The global pancreatic cancer treatment market was valued at $2.86 billion in 2023 and is projected to exceed $10.69 billion by 2032, with a compound annual growth rate (CAGR) of 15.8% [5] - Factors driving market growth include unhealthy lifestyles, alcohol consumption, and obesity, which are primary causes of pancreatic cancer [5]

Core Viewpoint - AngioDynamics (ANGO) has experienced a significant downtrend, with a 15.9% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1][3]. Group 1: Stock Performance - ANGO's stock has declined 15.9% in the last four weeks, indicating strong selling pressure [1]. - The stock is currently in oversold territory, as indicated by an RSI reading of 24.7, suggesting that selling may be exhausting [3]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that ANGO will report better earnings than previously predicted, with a 0.8% increase in the consensus EPS estimate over the last 30 days [3]. - ANGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [3].

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago quarter’s adjusted loss per share of 12 cents. The metric was also narrower than the Zacks Consensus Estimate of 15 cents.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC, Midline, and tip location product portfolios, and discontinued RadioFrequency and Syntrax support catheter products), adjusted loss per share in first-quarter fiscal 2025 was 11 ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioDyn ...

AngioDynamics, Inc. (ANGO) is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance and successful geographic expansion. However, pricing pressure and macroeconomic factors are concerns.Shares of this Zacks Rank #1 (Strong Buy) company have lost 2.4% year to date against the industry's 8.3% growth. The S&P 500 Index has gained 20% in the said time frame.The company designs, manufactures and ...

Investors didn't like the medical technology company's fiscal 2025 Q1 update.Shares of AngioDynamics (ANGO -17.52%) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter update.AngioDynamics reported fiscal Q1 net sales of $67.5 million, up 1.1% year over year. This result was a little lower than the average analysts' revenue estimate of $67.93 million.The company posted a net loss of $12.8 million, or ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 First Quarter Earnings Call. At this time all participants are in listen-only mode. A question-and-answer session w ...

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.Shares of AngioDynamics, Inc. ANGO fell sharply during Thursday's session following first-quarter results.AngioDynamics posted first-quarter adjusted loss of 11 cents per share, compared to market estimates of a loss of 15 cents per share. The company's quarterly sales came in at $67.491 million versus expectations of $67.933 million.AngioDynamics shares dipped 15.6% to $6.45 on Thursday.Here are some other big sto ...